

CADTH REIMBURSEMENT REVIEW

Pharmacoeconomic Report

Polatuzumab Vedotin (POLIVY)

(Hoffmann-La Roche Limited)

Indication: In combination with bendamustine and rituximab for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma, not otherwise specified, who are not eligible for autologous stem cell transplant and have received at least one prior therapy.

Version: Final

Publication Date: April 21, 2021

Report Length: 16 Pages

Disclaimer: The information in this document is intended to help Canadian health care decision-makers, health care professionals, health systems leaders, and policy-makers make well-informed decisions and thereby improve the quality of health care services. While patients and others may access this document, the document is made available for informational purposes only and no representations or warranties are made with respect to its fitness for any particular purpose. The information in this document should not be used as a substitute for professional medical advice or as a substitute for the application of clinical judgment in respect of the care of a particular patient or other professional judgment in any decision-making process. The Canadian Agency for Drugs and Technologies in Health (CADTH) does not endorse any information, drugs, therapies, treatments, products, processes, or services.

While care has been taken to ensure that the information prepared by CADTH in this document is accurate, complete, and up-to-date as at the applicable date the material was first published by CADTH, CADTH does not make any guarantees to that effect. CADTH does not guarantee and is not responsible for the quality, currency, propriety, accuracy, or reasonableness of any statements, information, or conclusions contained in any third-party materials used in preparing this document. The views and opinions of third parties published in this document do not necessarily state or reflect those of CADTH.

CADTH is not responsible for any errors, omissions, injury, loss, or damage arising from or relating to the use (or misuse) of any information, statements, or conclusions contained in or implied by the contents of this document or any of the source materials.

This document may contain links to third-party websites. CADTH does not have control over the content of such sites. Use of third-party sites is governed by the third-party website owners' own terms and conditions set out for such sites. CADTH does not make any guarantee with respect to any information contained on such third-party sites and CADTH is not responsible for any injury, loss, or damage suffered as a result of using such third-party sites. CADTH has no responsibility for the collection, use, and disclosure of personal information by third-party sites.

Subject to the aforementioned limitations, the views expressed herein are those of CADTH and do not necessarily represent the views of Canada's federal, provincial, or territorial governments or any third-party supplier of information.

This document is prepared and intended for use in the context of the Canadian health care system. The use of this document outside of Canada is done so at the user's own risk.

This disclaimer and any questions or matters of any nature arising from or relating to the content or use (or misuse) of this document will be governed by and interpreted in accordance with the laws of the Province of Ontario and the laws of Canada applicable therein, and all proceedings shall be subject to the exclusive jurisdiction of the courts of the Province of Ontario, Canada.

The copyright and other intellectual property rights in this document are owned by CADTH and its licensors. These rights are protected by the Canadian *Copyright Act* and other national and international laws and agreements. Users are permitted to make copies of this document for non-commercial purposes only, provided it is not modified when reproduced and appropriate credit is given to CADTH and its licensors.

About CADTH: CADTH is an independent, not-for-profit organization responsible for providing Canada's health care decision-makers with objective evidence to help make informed decisions about the optimal use of drugs, medical devices, diagnostics, and procedures in our health care system.

Funding: CADTH receives funding from Canada's federal, provincial, and territorial governments, with the exception of Quebec.

Table of Contents

List of Tables	4
Abbreviations	5
Executive Summary	6
Conclusions	8
Stakeholder Input Relevant to the Economic Review	9
Economic Review	10
Appendix 1: Cost Comparison Table	11
Appendix 2: Submission Quality	12
Appendix 3: Additional Information on the Submitted Economic Evaluation	13
Appendix 4: Additional Details on the CADTH Reanalyses and Sensitivity Analyses of the Economic Evaluation	14
Appendix 5: Submitted BIA and CADTH Appraisal	15
References.....	16

List of Tables

Table 1: Submitted for Review.....	6
Table 2: Summary of Economic Evaluation.....	7

Abbreviations

AE	adverse event
ASCT	autologous stem cell transplant
BSA	body surface area
CAR-T	chimeric antigen receptor T-cell
CEAC	cost effectiveness acceptability curve
CEOP	rituximab + cyclophosphamide + etoposide + vincristine + prednisone
CEPP/PEP-C	prednisone + etoposide + procarbazine + cyclophosphamide
CHOP	prednisone + cyclophosphamide + doxorubicin + vincristine
CVP	cyclophosphamide + vincristine + prednisolone
DHAP	dexamethasone + cisplatin + cytarabine
DICEP	dose-intensive cyclophosphamide + etoposide + cisplatin
DLBCL	diffuse large B-cell lymphoma
EPOCH	etoposide, prednisone, vincristine, cyclophosphamide, hydroxydaunorubicin
GDP	gemcitabine + dexamethasone + cisplatin
GEMOX	gemcitabine + oxaliplatin
ICE	ifosfamide + cisplatin or carboplatin + etoposide
OS	overall survival
PFS	progression-free survival
QALY	quality-adjusted life year
RWD	real-world data
WTP	willingness to pay

Executive Summary

The executive summary is comprised of two tables (Table 1 and Table 2) and a conclusion.

Table 1: Submitted for Review

Item	Description
Drug product	Polatuzumab vedotin (Polivy), vial for intravenous (IV) infusion
Submitted price	Polatuzumab vedotin: \$14,750.00 per 140 mg vial
Indication	Treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma, not otherwise specified, who are not eligible for autologous stem cell transplant and have received at least one prior therapy
Health Canada approval status	NOC/c
Health Canada review pathway	Advance consideration under NOC/c
NOC date	July 09, 2020
Reimbursement request	As per indication.
Sponsor	Hoffmann-La Roche Limited
Submission history	Previously reviewed: No

IV, intravenous; NOC/c = Notice of Compliance with Conditions

Table 2: Summary of Economic Evaluation

Component	Description
Type of economic evaluation	Cost-utility analysis Partitioned survival model
Target population	Adult patients with relapsed or refractory diffuse large B-cell lymphoma (r/r DLBCL), not otherwise specified, who are not eligible for autologous stem cell transplant and have received at least one prior therapy.
Treatments	Polatuzumab vedotin + bendamustine + rituximab (Pola-BR)
Comparators	Basket of treatment regimens ("basket comparator") used in Canadian practice as reflected by the Alberta O2 real-world dataset. These regimens include: R-GDP, R-DICEP, Dexamethasone-Etoposide, pembrolizumab, PEP-C, R-CEOP, BP, R-Ino, R-BV
Perspective	Canadian publicly funded health care payer
Outcomes	QALYs, LYs
Time horizon	Lifetime (20 years)
Key data source	Relative effects of pola-BR for PFS and OS compared to a basket comparator: a propensity score method was applied to individual participant data from the GO29365 trial (N=91) and the Alberta O2 real-world data (RWD) registry (N=42)
Submitted results for base case and key scenario analyses	<ul style="list-style-type: none"> Base-case analysis: pola-BR was associated with an ICER of \$57,711 per QALY (\$122,932 incremental costs, 1.750 incremental QALYs) compared to the basket comparator. Scenario analyses: Pola-BR was: <ul style="list-style-type: none"> associated with an ICER of \$58,909 per QALY when compared with BR, dominant (less costly and more effective) compared to tisagenlecleucel, less costly and less effective than axicabtagene ciloleucel.
Key limitations	<ul style="list-style-type: none"> The comparative efficacy of pola-BR and the basket comparator is highly uncertain. Given the lack of direct evidence, the sponsor derived the comparative efficacy using a propensity score matching analysis approach. CADTH identified major limitations related to the size of the cohort used, the ability to efficiently weight between RWD and trial data, and the differences between study arms. This introduced significant uncertainty into the indirect comparison that could not be sufficiently accounted for within the submitted economic analysis, and any analyses based on these data must be viewed with caution. The sponsor pooled the efficacy data for pola-BR from different patient cohorts within the GO29365 trial. CADTH identified concerns with the data pooling such as notable differences in the trial design that may introduce (methodological and clinical) heterogeneity between cohorts. Without proper adjustment for the heterogeneity, pooling these cohorts may introduce biases into the results. The clinical experts consulted on this review suggested that the predicted survival rates in the sponsor's model, especially for patients with progressed disease, were overestimated and not aligned with the observed and expected survival for this patient population. CADTH identified errors in the sponsor's model: including use of a non-approved vial size (30 mg), excluding SEB price for rituximab, including anti-CD20 use as subsequent treatment, and using a small number of iterations. CADTH was able to correct for these errors.
CADTH reanalysis results	<ul style="list-style-type: none"> Due to the limitations identified with the sponsor's model, including the available data and model mechanics, CADTH could not determine a CADTH base case. To provide a more credible analysis prior to exploring different scenarios for the clinical data, the sponsor's corrected based case resulted in an ICER of \$70,264 per QALY. Based on CADTH's exploratory analyses examining different assumptions regarding the clinical data, the cost-effectiveness of Pola-BR could range from \$67,000 per QALY to \$147,000 per QALY compared with the basket comparator. However, there is substantial uncertainty associated with these estimates, given the limitations identified with the comparative clinical information.

BP = bendamustine + prednisone; CAR-T = chimeric antigen receptor T-cell therapy; Dexa-Etop = dexamethasone + etoposide; ICER = incremental cost-effectiveness ratio; LY = life-year; PEP-C = prednisone + etoposide + procarbazine + cyclophosphamide; Pola-BR = polatuzumab vedotin + bendamustine + rituximab; QALY= quality-adjusted life-year; R-BV = rituximab + brentuximab vedotin; R-CEOP = rituximab + cyclophosphamide + etoposide + vincristine + prednisone; R-DICEP = rituximab + dose-intensive cyclophosphamide + etoposide + cisplatin; R-GDP = rituximab + gemcitabine + dexamethasone + cisplatin; R-Ino = rituximab + inotuzumab ozogamicin; RWD = real world data; SEB = subsequent entry biologic.

Conclusions

Due to the lack of direct clinical evidence comparing pola-BR to current standard of care used in Canada, the sponsor derived comparative effectiveness estimates from the GO29365 trial and Alberta real-world database using a propensity score matching analysis approach. CADTH identified major limitations with this analysis, and determined that no firm conclusions could be drawn on the comparative effectiveness of pola-BR compared with the basket comparator. CADTH was unable to address several major limitations, including the lack of direct evidence on comparative clinical data with comparators indicated and used in Canadian clinical practice, the use of a basket comparator of nine currently used treatments for r/r DLBCL, and substantial uncertainty residual confounders from the submitted propensity score analysis.

The issues with the clinical data prohibit a reasonable assessment of cost-effectiveness. As such, a CADTH base case could not be derived. CADTH undertook reanalyses to correct the sponsor's base case by using an approved vial size (140 mg) of polatuzumab, applying SEB price for rituximab, removing anti-CD20 use as subsequent treatment, and increasing the number of simulations, as well as present a series of exploratory analyses to highlight the uncertainty associated with the sponsor's ICER. When correcting for available vial size of pola-BR, using appropriate costs for rituximab, and increasing iterations to reduce variance in the ICER, pola-BR was associated with ICER of \$70,264 per QALY compared to the basket comparator. CADTH undertook a series of exploratory reanalyses which suggested that the ICER of pola-BR was likely to be higher than estimated by the sponsor; when focusing on just the reanalyses based on alternate clinical data assumptions, the ICER for pola-BR compared with the basket comparator ranged from \$67,000 per QALY to \$147,000 per QALY. However, all of these results suggest that pola-BR controls the disease better than a basket comparator post-progression which was considered hypothetical and without biological support by clinical experts consulted by CADTH. The exploratory analyses resulting in higher ICERs are due to fewer incremental life years and QALYs being accrued in the post-progression state. Based on these exploratory analyses, a price reduction for polatuzumab of between 35% and 84% would be required for pola-BR to become cost-effective at a WTP threshold of \$50,000 per QALY compared with the basket comparator, however, the uncertainty identified with the comparative clinical information and modelling approach suggest caution when interpreting these results.

Based on the sponsor's submitted budget impact analysis, the total budget impact of reimbursing pola-BR under the full Health Canada indication was estimated to be \$ [REDACTED] over the first three years. CADTH re-analysis of the sponsor's submitted BIA suggests that the estimated budget impact of introducing pola-BR would be \$66,588,692 over the first three years.

Stakeholder Input Relevant to the Economic Review

This section outlines the technical details of the pCODR Economic Guidance Panel's evaluation of the economic evidence that is summarized in the executive summary. In accordance with the *Disclosure of Information Guidelines for the CADTH Pan-Canadian Oncology Drug Review*, this section is not eligible for disclosure. It was provided to the pCODR Expert Review Committee (pERC) for their deliberations and the participating drug programs for their information.

Economic Review

This section outlines the technical details of the pCODR Economic Guidance Panel's evaluation of the economic evidence that is summarized in the executive summary. In accordance with the *Disclosure of Information Guidelines for the CADTH Pan-Canadian Oncology Drug Review*, this section is not eligible for disclosure. It was provided to the pCODR Expert Review Committee (pERC) for their deliberations and the participating drug programs for their information.

Appendix 1: Cost Comparison Table

This section outlines the technical details of the pCODR Economic Guidance Panel's evaluation of the economic evidence that is summarized in the executive summary. In accordance with the *Disclosure of Information Guidelines for the CADTH Pan-Canadian Oncology Drug Review*, this section is not eligible for disclosure. It was provided to the pCODR Expert Review Committee (pERC) for their deliberations and the participating drug programs for their information.

Appendix 2: Submission Quality

This section outlines the technical details of the pCODR Economic Guidance Panel's evaluation of the economic evidence that is summarized in the executive summary. In accordance with the *Disclosure of Information Guidelines for the CADTH Pan-Canadian Oncology Drug Review*, this section is not eligible for disclosure. It was provided to the pCODR Expert Review Committee (pERC) for their deliberations and the participating drug programs for their information.

Appendix 3: Additional Information on the Submitted Economic Evaluation

This section outlines the technical details of the pCODR Economic Guidance Panel's evaluation of the economic evidence that is summarized in the executive summary. In accordance with the *Disclosure of Information Guidelines for the CADTH Pan-Canadian Oncology Drug Review*, this section is not eligible for disclosure. It was provided to the pCODR Expert Review Committee (pERC) for their deliberations and the participating drug programs for their information.

Appendix 4: Additional Details on the CADTH Reanalyses and Sensitivity Analyses of the Economic Evaluation

This section outlines the technical details of the pCODR Economic Guidance Panel's evaluation of the economic evidence that is summarized in the executive summary. In accordance with the *Disclosure of Information Guidelines for the CADTH Pan-Canadian Oncology Drug Review*, this section is not eligible for disclosure. It was provided to the pCODR Expert Review Committee (pERC) for their deliberations and the participating drug programs for their information.

Appendix 5: Submitted BIA and CADTH Appraisal

This section outlines the technical details of the pCODR Economic Guidance Panel's evaluation of the economic evidence that is summarized in the executive summary. In accordance with the *Disclosure of Information Guidelines for the CADTH Pan-Canadian Oncology Drug Review*, this section is not eligible for disclosure. It was provided to the pCODR Expert Review Committee (pERC) for their deliberations and the participating drug programs for their information.

References

1. Pharmacoeconomic evaluation. In: pan-Canadian Oncology Drug Review sponsor submission: Polivy (polatuzumab vedotin), 140 mg vial for infusion. Mississauga (ON): Hoffmann-La Roche Ltd; 2020 Sep 29.
2. Polivy (polatuzumab vedotin for injection): lyophilized powder for solution for intravenous infusion only, 140 mg single-use vial [product monograph]. Mississauga (ON): Hoffmann-La Roche Limited; 2020 Jul 09.
3. Clinical Study Report: GO29365. A Phase Ib/II study evaluating the safety, tolerability, and anti-tumor activity of polatuzumab vedotin (DCDS4501A) in combination with rituximab (R) or obinutuzumab (G) plus bendamustine (B) in relapsed or refractory follicular or diffuse large B-cell lymphoma [internal sponsor's report]. Mississauga (ON): Hoffmann-La Roche Limited; 2020.
4. Propensity score weighted comparison of POLIVY™ (polatuzumab vedotin) plus bendamustine and rituximab (BR) (GO29365 Trial) to Alberta O2 RWD for the treatment of transplant-ineligible R/R DLBCL [internal sponsor's report]. In: pan-Canadian Oncology Drug Review sponsor submission: Polivy (polatuzumab vedotin), 1.8 mg/kg for infusion. Mississauga (ON): Hoffman-LaRoche; 2020.
5. National Institute for Health Care and Excellence. Axicabtagene ciloleucel for treating diffuse large B-cell lymphoma and primary mediastinal large B-cell lymphoma after 2 or more systemic therapies. (*Technology appraisal guidance TA559*) 2019; <https://www.nice.org.uk/guidance/ta559>. Accessed 2021 Feb 20.
6. National Institute for Health Care and Excellence. Pixantrone monotherapy for treating multiply relapsed or refractory aggressive non-Hodgkin's B-cell lymphoma. (*Technology appraisal guidance TA306*) 2014; <https://www.nice.org.uk/guidance/ta306>. Accessed 2021 Feb 20.
7. Walker H, Anderson M, Farahati F, et al. Resource use and costs of end-of-Life/palliative care: Ontario adult cancer patients dying during 2002 and 2003. *J Palliat Care*. 2011;27(2):79-88.
8. Van Den Neste E, Schmitz N, Mounier N, et al. Outcome of patients with relapsed diffuse large B-cell lymphoma who fail second-line salvage regimens in the International CORAL study. *Bone Marrow Transplant*. 2016;51(1):51-57.
9. Crump M, Neelapu SS, Farooq U, et al. Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study. *Blood*. 2017;130(16):1800-1808.
10. Betts KA, Thuresson PO, Felizzi F, et al. US cost-effectiveness of polatuzumab vedotin, bendamustine and rituximab in diffuse large B-cell lymphoma. *J Comp Eff Res*. 2020;9(14):1003-1015.
11. Patel KK, Isufi I, Kothari S, Foss F, Huntington S. Cost-effectiveness of polatuzumab vedotin in relapsed or refractory diffuse large B-cell lymphoma. *Leuk Lymphoma*. 2020;61(14):3387-3394.
12. DeltaPA. Ottawa (ON): IQVIA; 2020. <https://www.iqvia.com/>. Accessed 2020 Nov 19.
13. Ontario Ministry of Health, Ontario Ministry of Long-Term Care. Ontario drug benefit formulary/comparative drug index. 2020; <https://www.formulary.health.gov.on.ca/formulary/>. Accessed 2021 Mar 10.
14. Exceptional Access Program (EAP). Toronto (ON): Ontario Ministry of Health; Ontario Ministry of Long-Term Care; 2020: http://www.health.gov.on.ca/en/pro/programs/drugs/odbf/odbf_except_access.aspx. Accessed 2021 Mar 10.
15. Cancer Care Ontario: funded evidence-informed regimens. 2020; <https://www.cancercareontario.ca/en/drugformulary/regimens>. Accessed 2021 Mar 10.
16. Guideline Resource Unit. Lymphoma: clinical practice guideline LYHE-002, v12. Edmonton (AB): Cancer Care Alberta, Alberta Health Services; 2019: <https://www.albertahealthservices.ca/assets/info/hp/cancer/if-hp-cancer-guide-lyhe002-lymphoma.pdf>. Accessed 19 Nov 2020.
17. Vijay A, Duan Q, Henning JW, et al. High dose salvage therapy with dose intensive cyclophosphamide, etoposide and cisplatin may increase transplant rates for relapsed/refractory aggressive non-Hodgkin lymphoma. *Leuk Lymphoma*. 2013;54(12):2620-2626.
18. Cancer Care Ontario: drugs. 2020; <https://www.cancercareontario.ca/en/drugformulary/drugs>. Accessed 2020 Nov 19.
19. Mounier N, El Gnaoui T, Tilly H, et al. Rituximab plus gemcitabine and oxaliplatin in patients with refractory/relapsed diffuse large B-cell lymphoma who are not candidates for high-dose therapy. A phase II Lymphoma Study Association trial. *Haematologica*. 2013;98(11):1726-1731.
20. Czuczman MS, Trnecy M, Davies A, et al. A Phase 2/3 Multicenter, Randomized, Open-Label Study to Compare the Efficacy and Safety of Lenalidomide Versus Investigator's Choice in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma. *Clin Cancer Res*. 2017;23(15):4127-4137.
21. Canadian Cancer Statistics Advisory Committee. Canadian cancer statistics 2019. Toronto (ON): Canadian Cancer Society; 2019: <https://www.cancer.ca/~media/cancer.ca/CW/cancer%20information/cancer%20101/Canadian%20cancer%20statistics/Canadian-Cancer-Statistics-2019-EN.pdf?la=en>. Accessed 2021 Mar 10.
22. Lymphoma Canada. Diffuse Large B cell Lymphoma (DLBCL). 2020; <https://www.lymphoma.ca/diffuse-large-b-cell-lymphoma/>. Accessed 2020 Nov 20.
23. Sehn LH, Herrera AF, Flowers CR, et al. Polatuzumab Vedotin in Relapsed or Refractory Diffuse Large B-Cell Lymphoma. *J Clin Oncol*. 2020;38(2):155-165.
24. Budget Impact Analysis. In: pan-Canadian Oncology Drug Review sponsor submission: Polivy (polatuzumab vedotin), 1.8 mg/kg for infusion. Mississauga (ON): Hoffmann-La Roche Ltd; 2020 Sep 29.
25. Government of Canada. Register of Innovative Drugs. Products for Human Use - Expired Data Protection Period Table: bendamustine hydrochloride entry. 2020; <https://www.canada.ca/en/health-canada/services/drugs-health-products/drug-products/applications-submissions/register-innovative-drugs.html>. Accessed 2020 Nov 20.